Novel blood test could quash endometrial cancer
An exciting advancement in the early detection of endometrial cancer (cancer of the uterus lining) has secured $600,000 to further a novel blood test to identify the disease when highly treatable.
Supported by the Cancer Institute of NSW, female reproductive health researchers from the University of Newcastle and Hunter Medical Research Institute have developed and patented a blood test for endometrial cancer able to accurately detect the early stages of the disease.
Endometrial cancer is the most common malignancy of the female reproductive tract and the fourth most common cancer in women, and its incidence is increasing. Neither chemotherapy nor radiation therapy significantly increases long-term survival.
Although surgery is effective in early-stage cancers, the median survival of women with advanced endometrial cancer is less than one year. One significant limitation has been the lack of a blood test for screening and early detection of endometrial cancer, where it can be easily treated with surgery.
Led by Dr Arnab Ghosh in collaboration with clinician Dr Ken Jaaback and Professor Pradeep Tanwar, the project will further the groundbreaking early intervention.
Related news
- Beginning teachers deliver same quality of teaching as experienced teachers
- Catholic women’s cries for change to be heard at the Vatican on IWD
- HMRI Poo Palace puts digestive issues conversation on the menu
- Explore how Delprat Garden sprouts new life on contaminated land
- Papers of Newcastle Aboriginal activist to see the light of day: Stan Masterton Collection
The University of Newcastle acknowledges the traditional custodians of the lands within our footprint areas: Awabakal, Darkinjung, Biripai, Worimi, Wonnarua, and Eora Nations. We also pay respect to the wisdom of our Elders past and present.